Table 1.

Multivariable analysis of M‐protein dynamic features and identified baseline variables for PFS in the POLLUX (n = 569) study

Variable, unit	HRs (95% CIs) based on M‐protein data up to the indicated time cutoffs
	Baseline	1 month	2 months	3 months	6 months	All data
Maximum reduction of M‐protein, %	‐	0.715 (0.426–1.2)	1.19 (1.05–1.35)	1.17 (1.06–1.3)	1.34 (1.27–1.41)	1.39 (1.32–1.48)
Last observed M‐protein change from baseline, %	‐	10.2 (1.94–54)	1.1 (0.86–1.41)	1.01 (0.705–1.44)	1.23 (0.831–1.82)	0.903 (0.63–1.29)
Rate of M‐protein change, % per week	‐	1.5 (0.899–2.51)	1.02 (0.921–1.14)	1.07 (0.986–1.16)	1.01 (0.984–1.03)	1.03 (1.01–1.05)
Time from MM diagnosis to randomization, years	1.1 (1.04–1.16)	0.947 (0.9–0.997)	0.936 (0.888–0.986)	0.943 (0.896–0.993)	0.947 (0.9–0.997)	0.945 (0.897–0.997)
Cytogenetic risk high vs. standard	1.92 (1.30–2.83)	1.96 (1.33–2.89)	1.77 (1.19–2.64)	1.76 (1.17–2.65)	1.77 (1.18–2.66)	1.72 (1.15–2.58)
Prior thalidomide yes vs. no	1.45(1.06–1.98)	1.38 (0.993–1.91)	1.28 (0.926–1.76)	1.14 (0.83–1.58)	1.22 (0.886–1.68)	1.22 (0.883–1.68)
Prior PI yes vs. no	1.78 (1.07–2.96)	1.76 (1.05–2.94)	1.57 (0.942–2.61)	1.43 (0.86–2.38)	1.37 (0.82–2.27)	1.37 (0.82–2.28)
Type of myeloma IgG vs. non‐IgG	0.565 (0.415–0.77)	0.55 (0.402–0.751)	0.489 (0.356–0.672)	0.506 (0.367–0.698)	0.51 (0.371–0.701)	0.493 (0.358–0.679)
Hemoglobin, g/L	0.808 (0.736– 0.887)	0.789 (0.717–0.868)	0.807 (0.732–0.89)	0.802 (0.728–0.884)	0.803 (0.73–0.884)	0.814 (0.74–0.896)
Bone marrow plasma cells, %	0.94 (0.892–0.991)	1.12 (1.05–1.18)	1.12 (1.06–1.19)	1.12 (1.06–1.19)	1.11 (1.05–1.18)	1.12 (1.05–1.18)

For hemoglobin (g/L), bone marrow plasma cells (%), maximum reduction of M‐protein (%), and last observed M‐protein change from baseline (%), the hazard ratio is associated with each 10‐unit increase.